Pharma Report on Depression – Pipeline Review, H2 2020

Source: https://www.researchbymarkets.com/report/depression-pipeline-review-h2-2020-645826.html

Depression – Pipeline Review, H2 2020

Summary

Depression – Pipeline Review, H2 2020, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights

Depression – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 2, 17, 37, 46, 5, 92, 32 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 14 and 8 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Adamed Sp zoo
Adare Pharma Solutions
Addex Therapeutics Ltd
Aision Biotechnologies Inc
Alexza Pharmaceuticals Inc
Alkermes Plc
Allergan Ltd
Amorsa Therapeutics Inc
Anavex Life Sciences Corp
Angelini Group
Antheia Inc
Asulon Therapeutics Inc
Atai Life Sciences AG
Athira Pharma Inc
Avanir Pharmaceuticals Inc
Avicanna Inc
Axsome Therapeutics Inc
Azevan Pharmaceuticals Inc
Baergic Bio Inc
Beloteca Inc
Biohaven Pharmaceutical Holding Company Ltd
Bionomics Ltd
BioXcel Therapeutics Inc
Blackthorn Therapeutics Inc
Blue Oak Pharmaceuticals Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calico LLC
Camino Pharma LLC
Cellix Bio Pvt Ltd
Celon Pharma SA
CGeneTech (Suzhou China) Co Ltd
Chase Therapeutics Corp
Chengdu Jinrui Foundation Biotechnology Co Ltd
Clexio Biosciences Ltd
Compass Pathways Ltd
CSPC Pharmaceutical Group Ltd
CuroNZ Ltd
Cybin Therapeutics Inc
Delpor Inc
Denovo Biopharma LLC
Douglas Pharmaceuticals Ltd
Dracen Pharmaceuticals Inc
Eisai Co Ltd
Eleusis Ltd
Eli Lilly and Co
ES Therapeutics LLC
Evecxia Inc
Evotec SE
Fabre-Kramer Pharmaceuticals Inc
Gabather AB
Gilgamesh Pharmaceuticals Inc
GlaxoSmithKline Plc
GliaCure Inc
GNT Pharma Co Ltd
Guangzhou-Sheng Jian Chi Pharmaceutical Co Ltd
GW Pharmaceuticals Plc
H. Lundbeck AS
HEC Pharm Co Ltd
HolsboerMaschmeyer NeuroChemie GmbH
Hua Medicine Shanghai Ltd
Iltoo Pharma
Impel NeuroPharma Inc
Initiator Pharma AS
Intas Pharmaceuticals Ltd
IntelGenx Corp
Intra-Cellular Therapies Inc
INVENT Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Gibel Pharmaceutical Co Ltd
Jiangsu Nhwa Pharmaceutical Co Ltd
Jina Pharmaceuticals Inc
Johnson & Johnson
Kissei Pharmaceutical Co Ltd
Klaria Pharma Holding AB
Korea Pharma Co Ltd
Krenitsky Pharmaceuticals Inc
Kures Inc
Lactocore Inc
Lead Discovery Center GmbH
Les Laboratoires Servier SAS
Ligand Pharmaceuticals Inc
Lixte Biotechnology Holdings Inc
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
Mapreg SAS
Marinus Pharmaceuticals Inc
MD Healthcare Inc
Medlab Clinical Ltd
MElkin Pharmaceuticals
Mental-Heal Ltd
Meta-IQ ApS
Methylation Sciences Inc
miCure Therapeutics Ltd
Navitor Pharmaceuticals Inc
Neonc Technologies Inc
Neurocentrx Pharma Ltd
Neurocrine Biosciences Inc
Neurocyte Therapeutics Inc
Neurolixis Inc
NeuroNascent Inc
NeuroPharm Inc
NeuroRx Inc
Neurotrope Bioscience Inc
Nippon Chemiphar Co Ltd
Novartis AG
Nubiyota LLC
Omeros Corp
Orexigen Therapeutics Inc
Otsuka Holdings Co Ltd
Otsuka Pharmaceutical Co Ltd
Overseas Pharmaceuticals Ltd
OWP Pharmaceuticals Inc
Pfizer Inc
PharmaMax Corp
Pharmnovo AB
PharmoRx Therapeutics Inc
Phytecs
PNB Vesper Life Science Pvt Ltd
Praxis Precision Medicines Inc
Primetime Life Sciences LLC
Protagenic Therapeutics Inc
Prous Institute for Biomedical Research SA
Psy Therapeutics Inc
PsyBio Therapeutics Inc
Relmada Therapeutics Inc
Repurposed Therapeutics Inc
Reven Pharmaceuticals Inc
Reviva Pharmaceuticals Inc
Richter Gedeon Nyrt
Sage Therapeutics Inc
Seelos Therapeutics, Inc.
Seneca Biopharma Inc
Shanghai SIMR Biotech Co Ltd
Shanghai Synergy Pharmaceutical Sciences Co Ltd
Shenox Pharmaceuticals LLC
Siragen Pharmaceuticals Inc
Sirtsei Pharmaceuticals Inc
SK Biopharmaceuticals Co Ltd
Small Pharma Ltd
Sosei Heptares
Sound Pharmaceuticals Inc
Sumitomo Dainippon Pharma Co Ltd
Sun Pharma Advanced Research Company Ltd
Sunovion Pharmaceuticals Inc
Supernus Pharmaceuticals Inc
Suven Life Sciences Ltd
SyneuRx International Corp
Taisho Pharmaceutical Holdings Co Ltd
Tasly Holding Group Co Ltd
Techfields Pharma Co Ltd
Terran Biosciences Inc
Tonix Pharmaceuticals Holding Corp
Trevena Inc
Vanda Pharmaceuticals Inc
Viridia Life Sciences
VistaGen Therapeutics Inc
Whan In Pharm Co Ltd
XWPharma
Yantai YenePharma Co Ltd
Yungjin Pharm Co Ltd
Zhejiang Jinhua Conba Bio-pharm Co Ltd
Zysis Ltd


For queries regarding this report: https://www.researchbymarkets.com/sample-request/645826

Contact Us:
ResearchByMarkets.com
Ritesh Tiwari, Director
enquiry@researchbymarkets.com
USA: +1-800-416-3124
https://www.researchbymarkets.com
https://www.researchbymarkets.com/aboutus

Follow us on Social Media:
Facebook: https://www.facebook.com/researchbymarkets/
LinkedIn: https://www.linkedin.com/company/researchmarkets
Twitter: https://twitter.com/ResearchByMrkts

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: enquiry@researchbymarkets.com *Industry Press Release is a part of Research By Markets.